TruSight Cystic Fibrosis

FDA-regulated, CE-marked in vitro diagnostic (IVD) next-generation sequencing assay conveniently providing two cystic fibrosis tests in one product.

This product is only available in select locations. Please select the location where you would like this product to be shipped to see availability.

MiSeqDx Reagent Kit v3, Micro provides a flexible, cost-saving option for running a smaller batch size of 24-36 samples. This product is currently validated for exclusive use with the TruSight Cystic Fibrosis 139-Variant Assay. Available in select geographies.  

Overview

TruSight Cystic Fibrosis is an FDA-regulated in vitro diagnostic (IVD) NGS solution that consolidates two cystic fibrosis assays into a single workflow.  

  • Combines an ancestrally diverse variant panel with full CFTR sequencing  

  • Provides efficient library prep and highly flexible throughput

  • Generates a highly accurate and easily interpreted report 

TruSight Cystic Fibrosis 139-Variant Assay

Accurately detects 139 clinically relevant CFTR variants defined in the CFTR2 database as of August 2013.1   

  • Improves detection of CF-causing variants from 72 to ~91% sensitivity2 

  • Reduces additional testing with reliable results

  • Provides comprehensive detection across diverse demographics3  

TruSight Cystic Fibrosis Clinical Sequencing Assay 

Captures all variants in the protein coding regions and intron/exon boundaries for a complete view of the CFTR gene.

  • Delivers deep coverage (> 3000×) for detection accuracy with a Positive Agreement (PA) of 99.66% (includes polyTG/polyT variants) 

  • Removes demographic bias inherent in existing genotyping panels3 

  • Automatically detects polyTG/polyT variants 

  • Uncovers rare mutations not accounted for in standard tests 


Specifications


Required Products

  • TruSight Cystic Fibrosis Library Prep, which includes the necessary library prep reagents and indexes to support 96 samples
  • MiSeqDx Reagent Kit v3 or MiSeqDx Reagent Kit v3, Micro (for running a smaller batch size of 24-36 samples)
  • MiSeqDx Instrument

Optional products:

  • TruSeq Index Plate Fixture Kit (2 fixtures)
  • TruSeq Index Plate Fixture & Collar Kit (2 each)
/ Results

Applications

TruSight Cystic Fibrosis is an FDA-regulated, CE-marked IVD NGS assay that provides two cystic fibrosis tests for carrier screening, confirmatory diagnostic testing of newborns and children, initial testing to aid in diagnosis (TruSight Cystic Fibrosis 139-Variant Assay), and testing in atypical presentations or when other panels have failed to identify causative mutations (TruSight Cystic Fibrosis Clinical Sequencing Assay).  

Example workflow

1
Prep

TruSight Cystic Fibrosis 139-Variant Assay

TruSight Cystic Fibrosis Clinical Sequencing Assay

2
Sequence

MiSeqDx Reagent Kit v3, Micro

3
Analyze


Related applications and methods

Documentation

Product literature

Intended use

TruSight Cystic Fibrosis 139-Variant Assay

The Illumina TruSight Cystic Fibrosis 139-Variant Assay is a qualitative in vitro diagnostic system used to simultaneously detect 139 clinically relevant cystic fibrosis disease-causing mutations and variants of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood samples. The variants include those recommended in 2004 by the American College of Medical Genetics (ACMG)4 and in 2011 by the American College of Obstetricians and Gynecologists (ACOG).5

 

The test is intended for carrier screening in adults of reproductive age, in confirmatory diagnostic testing of newborns and children, and as an initial test to aid in the diagnosis of individuals with suspected cystic fibrosis. The results of this test are intended to be interpreted by a board-certified clinical molecular geneticist or equivalent and should be used in conjunction with other available laboratory and clinical information. This test is not indicated for use for newborn screening, fetal diagnostic testing, pre-implantation testing, or for stand-alone diagnostic purposes.

The test is intended to be used on the Illumina MiSeqDx instrument.

 

TruSight Cystic Fibrosis Clinical Sequencing Assay

The Illumina TruSight Cystic Fibrosis Clinical Sequencing Assay is a targeted sequencing in vitro diagnostic system that re-sequences the protein coding regions and intron/exon boundaries of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in genomic DNA isolated from human peripheral whole blood specimens collected in K2EDTA. The test detects single nucleotide variants and small indels within the region sequenced, and additionally reports on two deep intronic mutations and two large deletions. The test is intended to be used on the Illumina MiSeqDx instrument.

 

The test is intended to be used as an aid in the diagnosis of individuals with suspected cystic fibrosis (CF). This assay is most appropriate when the patient has an atypical or non-classic presentation of CF or when other mutation panels have failed to identify both causative mutations. The results of this test are intended to be interpreted by a board-certified clinical molecular geneticist or equivalent and should be used in conjunction with other available information including clinical symptoms, other diagnostic tests, and family history. This test is not indicated for use for stand-alone diagnostic purposes, fetal diagnostic testing, preimplantation testing, carrier screening, newborn screening, or population screening.

 

For  In Vitro Diagnostic Use

Contact an Illumina representative for regional availability.

Figures

CFTR regions sequenced with TruSight Cystic Fibrosis Clinical Sequencing Assay

CFTR regions sequenced by the assay include protein coding regions across all exons, intron/exon boundaries, ~100 nt of flanking sequence at the 5’ and 3’ UTRs, two deep intronic mutations (1811+1.6kbA>G, 3489+10kbC>T), two large deletions (CFTRdele2,3, CFTRdele22,23) and the PolyTG/PolyT region.

Clinically relevant CFTR variants on TruSight Cystic Fibrosis 139-Variant Assay

TruSight Cystic Fibrosis 139-Variant Assay detects 139 clinically relevant CFTR variants1

Mutations in the ACMG-23 list for CF screening
R347P 1717-1G>A 3849+10kbC>T
G85E G542X W1282X
R117H G551D 711+1G>T
621+1G>T R553X R560T
R334W 2184delA 1898+1G>A
A455E 2789+5G>A N1303K
I507del 3120+1G>A R1162X
F508del 3659delC  

Only a subset of variants included in the assay are listed. To view the full list of variants in the TruSight Cystic Fibrosis 139-Variant Assay, visit www.illumina.com/ TruSightCysticFibrosis.

TruSight Cystic Fibrosis Performance

TruSight Cystic Fibrosis 139-Variant Assay
Characteristic PAa NAb OAc
Accuracy 100% > 99.99% > 99.99%
Reproducibility 99.77% 99.88% 99.88%
TruSight Cystic Fibrosis Clinical Sequencing Assay
Characteristic PAa NAb OAc
Accuracy 99.66% > 99.99% > 99.99%
Reproducibility 99.22% 99.70% 99.70%

a. Positive Agreement (PA) is the number of samples with agreeing variant calls divided by the total number of samples with that variant as identified by the reference method.

b. Negative Agreement (NA) calculated across all wild-type (WT) positions by dividing the number of concordant WT positions by the total number of WT positions as defined by the reference methods.

c. Overall Agreement (OA) calculated across all reported positions by dividing the number of concordant wild-type and variant positions by the total number of reported positions as determined by the reference methods.

Library prep (1)

TruSight Cystic Fibrosis Library Prep

20036925

Supports both the TruSight Cystic Fibrosis 139-Variant Assay and the TruSight Cystic Fibrosis Clinical Sequencing Assay. Includes reagents for library preparation of genomic DNA isolated from 96 peripheral whole blood specimens. Purchase MiSeqDx sequencing reagents separately.

Sign in to add to cart or see pricing.

List Price:

Discounts:

Reagents (2)

MiSeq Dx Reagent Kit v3

20037124

Includes one flow cell and one prefilled cartridge containing clustering and sequencing reagents to support one run of sample libraries on the MiSeqDx System.

Sign in to add to cart or see pricing.

List Price:

Discounts:

MiSeq™Dx Reagent Kit v3, Micro

20063860

Includes one micro flow cell and one pre-filled cartridge containing clustering and sequencing reagents to support 24–36 prepared libraries on the MiSeqDx System when using the TruSight Cystic Fibrosis Library Prep.

Sign in to add to cart or see pricing.

List Price:

Discounts:

Accessory products (2)

TruSeq Index Plate Fixture Kit (2 fixtures)

FC-130-1005

Assists in correctly arranging index primers for PCR amplification step. Includes two (2) TruSeq Index Plate Fixtures.

Sign in to add to cart or see pricing.

List Price:

Discounts:

TruSeq Index Plate Fixture & Collar Kit (2 each)

FC-130-1007

Assists in correctly arranging index primers for PCR amplification step. Includes two (2) TruSeq Index Plate Fixtures and two (2) Plate Collars.

Sign in to add to cart or see pricing.

List Price:

Discounts:

Showing of

Selection summary

Product

Qty

Unit Price

FAQs

TruSight Cystic Fibrosis 139-Variant Assay detects 139 variants in the CFTR gene for carrier screening, confirmatory diagnostic testing of newborns and children, and initial diagnostic testing.

TruSight Cystic Fibrosis Clinical Sequencing Assay re-sequences the protein coding region and intron/exon boundaries of the CFTR gene for aiding in diagnosis, testing in atypical presentations and when other panels do not identify both causative mutations.

Yes, prepared libraries stored as diluted amplicon libraries (DALs) can be used up to 28 days after preparation when stored frozen. There is no difference between libraries prepared for use in the TruSight Cystic Fibrosis 139-Variant Assay and TruSight Cystic Fibrosis Clinical Sequencing Assay.

Yes, you can do reflex testing from the TruSight Cystic Fibrosis 139-Variant Assay to the TruSight Cystic Fibrosis Clinical Sequencing Assay when the patient has an atypical or nonclassical presentation of CF or when other mutation panels have failed to identify both causative mutations.

Both TruSight Cystic Fibrosis assays have been designed to run with the MiSeqDx Reagent Kit v3. The MiSeqDx v3 sequencing flow cell has been validated to support 24-96 tests of each assay per sequencing run. The MiSeqDx Reagent Kit v3, Micro supports batches of 24-36 samples.  TruSight Cystic Fibrosis has been validated to support a minimum of 24 samples per flow cell run.

/ Results

Order the NovaSeq X Series

Advanced chemistry, optics, and informatics combine to deliver exceptional speed and data quality, outstanding throughput and scalability.

MiSeq Reagent Kit v3

Optimized reagent kit that provides increased cluster density and read length, improving sequencing quality scores compared to earlier versions.

TruSight Oncology 500

Enable CGP with a large pan-cancer panel covering all major variant classes plus gene signatures (TMB, MSI, and HRD) from FFPE tissue.

Illumina DNA Prep

A fast, integrated workflow for preparing libraries for use in a wide range of sequencing applications.

References:

1. Clinical and Functional Translation of CFTR. www.cftr2.org. Accessed August 2013. 

2. Sosnay PR, Siklosi KR, Van Goor F, et al. Defining the disease liability of variants in the cystic fibrosis transmembrane conductance regulator gene. Nature Genetics. 2013;45(10):1160-1167. doi:10.1038/ng.2745

3. Hughes EE, Stevens CF, Saavedra-Matiz CA, et al. Clinical sensitivity of cystic fibrosis mutation panels in a diverse population. Human Mutation. 2016;37(2):201-208. doi:10.1002/humu.22927

4. Watson MS, Cutting GR, Desnick RJ, et al. Cystic fibrosis population carrier screening: 2004 revision of American College of Medical Genetics mutation panel. Genet Med. 2004;6(5):387-391. doi:10.1097/01.gim.0000139506.11694.7c

5. Committee on Genetics. The American College of Obstetricians and Gynecologists Committee Opinion No. 486: Update on carrier screening for cystic fibrosis. Obstet Gyncol. 2011;486:1-4. doi:https://pubmed.ncbi.nlm.nih.gov/21422883/

Speak with a specialist

Reach out for information about our products and services, or get answers to questions about our technology.